Impaired growth hormone secretion in fibromyalgia patients: Evidence for augmented hypothalamic somatostatin tone
Open Access
- 8 May 2002
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 46 (5), 1344-1350
- https://doi.org/10.1002/art.10209
Abstract
Objective To determine whether female fibromyalgia (FM) patients exhibit a normal growth hormone (GH) response to an acute exercise stressor, and to assess the importance of somatostatin tone in the generation of this GH response. Methods Twenty female FM patients were compared with 10 healthy female controls. All subjects exercised to volitional exhaustion on a treadmill. A standard metabolic cart was used to monitor pulse, blood pressure, electrocardiography, oxygen uptake, carbon dioxide output, anaerobic threshold, and maximal workload. Blood was drawn for GH and cortisol measurements 1 hour before exercise, immediately before exercise, immediately after exercise, and 1 hour after exercise. One month later, testing that was exactly similar was performed, except all subjects were given pyridostigmine bromide (Mestinon; 30 mg orally) 1 hour before exercise. Results Compared with controls, FM patients failed to exhibit a GH or cortisol response to acute exercise (P = 0.003). After administration of pyridostigmine, 1 hour before exercise, the GH levels of FM patients increased 8-fold (P = 0.001), to a value comparable with that of controls. Pyridostigmine did not increase the cortisol response to exercise in FM patients. Pyridostigmine alone did not stimulate GH secretion in FM patients, nor did it improve exercise-induced GH secretion in controls. FM patients with normal insulin-like growth factor 1 (IGF-1) levels had an impaired GH response to exercise. Conclusion Three new findings are reported: 1) FM patients have a reduced GH response to exercise, 2) pyridostigmine reverses this impaired response, and 3) defective GH secretion in FM can occur in patients with normal IGF-1 levels. Because pyridostigmine is known to reduce somatostatin tone, it is surmised that the defective GH response to exercise in FM patients probably results from increased levels of somatostatin, a hypothalamic hormone that inhibits GH secretion.Keywords
This publication has 46 references indexed in Scilit:
- Decreased Nocturnal Levels of Prolactin and Growth Hormone in Women with FibromyalgiaJournal of Clinical Endocrinology & Metabolism, 2001
- Neuroendocrine deficiency-mediated development and persistence of pain in fibromyalgia: a promising paradigm?Pain, 2000
- Hyposecretion of adrenal androgens and the relation of serum adrenal steroids, serotonin and insulin-like growth factor-1 to clinical features in women with fibromyalgiaPain, 1999
- Growth hormone in obesityInternational Journal of Obesity, 1999
- Pyridostigmine potentiates growth hormone (GH)-releasing hormone- induced GH release in both men and womenJournal of Clinical Endocrinology & Metabolism, 1993
- Pyridostigmine partially reverses dexamethasone-induced inhibition of the growth hormone response to growth hormone-releasing hormoneJournal of Endocrinology, 1992
- The american college of rheumatology 1990 criteria for the classification of fibromyalgiaArthritis & Rheumatism, 1990
- Use of the modified balke treadmill protocol for determining the aerobic capacity of women with fibromyalgiaArthritis & Rheumatism, 1989
- GH FEEDBACK OCCURS THROUGH MODULATION OF HYPOTHALAMIC SOMATOSTATIN UNDER CHOLINERGIC CONTROL: STUDIES WITH PYRIDOSTIGMINE AND GHRHClinical Endocrinology, 1987